CDT

CDT Equity Inc. NCM · CDT

$0.31 -0.04 (-11.83%)

Pullback · -1.61σ

+ Compare Open in Sniper

Price chart

Timeframe

Range

Loading…

Latest bar · CDT

Momentum reads · latest daily bar

Last

$0.31

-0.04 (-11.83%)

Mkt cap

$0M

Healthcare

RSI(14)

29.7

oversold

Stochastic %K

6.5

oversold

MFI(14)

13.1

oversold

ADX(14)

10.8

weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

Quarter	Revenue	Net income	Op income	FCF	Net margin	Op margin
2026-03-31	—	$-0.0B	$-0.0B	$-0.0B	—	—
2025-12-31	—	$-0.0B	$-0.0B	$-0.0B	—	—
2025-09-30	—	$-0.0B	$-0.0B	$-0.0B	—	—
2025-06-30	—	$-0.0B	$-0.0B	$-0.0B	—	—
2025-03-31	—	$-0.0B	$-0.0B	$-0.0B	—	—
2024-12-31	$nanB	$nanB	$nanB	$nanB	nan%	nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare CDT vs peers

Line CDT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing CDT MRK× JNJ×

Sector peers + LLY + UNH + ABBV + PFE + TMO

Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO

Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Verdict

Weighted score 0-100 across 3 tickers · best in green

CDT

score 36.7

4/5 inputs

Value score maxes at 100 with exceptional 90.9% FCF yield, but catastrophic momentum showing -99.93% from 52-week high kills ranking.

value 100quality 17momentum 0sentiment 0

MRK

score 50.9

5/5 inputs

Momentum category dominates at 100 with strong 10.71% one-month gain plus 40% insider buying driving second-place finish.

value 39growth 0quality 75momentum 100sentiment 67

JNJ

score 67.1

5/5 inputs

Growth ranks highest at 75 with 6.6% revenue expansion while balanced 97 momentum and 80 quality secure top position.

value 40growth 75quality 80momentum 97sentiment 46

Metric	CDT CDT Equity Inc.	MRK MRK	JNJ Johnson & Johnson
Snapshot
Price	0.31	127.5	253.04
Day %↕	-11.83	-0.1	1.23
1M %↕	-56.41	10.71	7.59
3M %↕	-91.13	10.43	7.89
YTD %↕	-99.13	19.77	22.04
Market cap	197779.0	314902609920.0	609122123776.0
ADV ($)	2207121.332607329	1319581140.0	2085141651.2352905
Beta	—	0.205	0.235
OdysseyHQ zone
Current zone	Pullback	Neutral	Neutral
Dist 21-EMA %	-44.73	2.82	0.93
Dist ATR (σ)	-1.61	0.96	0.38
OdysseyHQ grade	—	B	—
Confluence↕	1	3	1
Valuation
P/E (ttm)↕	—	36.01695	29.320972
P/E (fwd)↕	—	13.203829	19.727968
P/S↕	—	4.7880826	6.220038
EV/EBITDA↕	-0.112	12.141	18.429
P/B↕	-0.004027449	6.863695	7.500815
FCF yield↕	90.8849	0.0446	—
PEG↕	—	11.81	4.18
Growth
Revenue yoy↕	—	0.049	0.066
EPS yoy↕	—	—	-0.01
FCF yoy↕	—	—	—
Revenue trend 8Q
Quality
Gross margin↕	0.0	0.76725996	0.68097
Operating margin↕	0.0	0.38604	0.28605
Net margin↕	0.0	0.13586001	0.21482
ROE↕	-0.7101	0.18944	—
ROA↕	-0.25225002	0.12578	—
Debt / Equity↕	0.01	1.07	0.68
Interest cov.↕	-121.96	16.52	34.55
Technicals
RSI(14)	29.7	57.9	54.4
MACD signal	neutral	neutral	neutral
vs 50-DMA	-67.39	6.67	6.03
vs 200-DMA	-98.95	16.44	13.51
vs 52w high	-99.93	-3.22	-6.08
HV-30	232.8	33.7	29.3
Sentiment
Analyst rec↕	—	1.82143	1.91304
Target upside↕	—	5.13	6.68
Insider buy-sell 90d↕	-3	40	13
Risk
Short interest↕	6.59	1.27	1.23000005
Days to cover↕	0.01	2.48	2.96
Next earnings	—	2026-08-04	2026-10-13

CDT

CDT Equity Inc.

$0.31

-11.83%

Snapshot

Price 0.31

Day % -11.83

1M % -56.41

3M % -91.13

YTD % -99.13

Market cap 197779.0

ADV ($) 2207121.332607329

Beta —

OdysseyHQ zone

Current zone Pullback

Dist 21-EMA % -44.73

Dist ATR (σ) -1.61

OdysseyHQ grade —

Confluence 1

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA -0.112

P/B -0.004027449

FCF yield 90.8849

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.0

Operating margin 0.0

Net margin 0.0

ROE -0.7101

ROA -0.25225002

Debt / Equity 0.01

Interest cov. -121.96

Technicals

RSI(14) 29.7

MACD signal neutral

vs 50-DMA -67.39

vs 200-DMA -98.95

vs 52w high -99.93

HV-30 232.8

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d -3

Risk

Short interest 6.59

Days to cover 0.01

Next earnings —

Full CDT dashboard →

MRK

$127.50

-0.10%

Snapshot

Price 127.5

Day % -0.1

1M % 10.71

3M % 10.43

YTD % 19.77

Market cap 314902609920.0

ADV ($) 1319581140.0

Beta 0.205

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % 2.82

Dist ATR (σ) 0.96

OdysseyHQ grade B

Confluence 3

Valuation

P/E (ttm) 36.01695

P/E (fwd) 13.203829

P/S 4.7880826

EV/EBITDA 12.141

P/B 6.863695

FCF yield 0.0446

PEG 11.81

Growth

Revenue yoy 0.049

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.76725996

Operating margin 0.38604

Net margin 0.13586001

ROE 0.18944

ROA 0.12578

Debt / Equity 1.07

Interest cov. 16.52

Technicals

RSI(14) 57.9

MACD signal neutral

vs 50-DMA 6.67

vs 200-DMA 16.44

vs 52w high -3.22

HV-30 33.7

Sentiment

Analyst rec 1.82143

Target upside 5.13

Insider buy-sell 90d 40

Risk

Short interest 1.27

Days to cover 2.48

Next earnings 2026-08-04

Full MRK dashboard →

JNJ

Johnson & Johnson

$253.04

+1.23%

Snapshot

Price 253.04

Day % 1.23

1M % 7.59

3M % 7.89

YTD % 22.04

Market cap 609122123776.0

ADV ($) 2085141651.2352905

Beta 0.235

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % 0.93

Dist ATR (σ) 0.38

OdysseyHQ grade —

Confluence 1

Valuation

P/E (ttm) 29.320972

P/E (fwd) 19.727968

P/S 6.220038

EV/EBITDA 18.429

P/B 7.500815

FCF yield —

PEG 4.18

Growth

Revenue yoy 0.066

EPS yoy -0.01

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.68097

Operating margin 0.28605

Net margin 0.21482

ROE —

ROA —

Debt / Equity 0.68

Interest cov. 34.55

Technicals

RSI(14) 54.4

MACD signal neutral

vs 50-DMA 6.03

vs 200-DMA 13.51

vs 52w high -6.08

HV-30 29.3

Sentiment

Analyst rec 1.91304

Target upside 6.68

Insider buy-sell 90d 13

Risk

Short interest 1.23000005

Days to cover 2.96

Next earnings 2026-10-13

Full JNJ dashboard →

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅	Mkt cap ⇅	P/E ⇅	Fwd P/E ⇅	P/S ⇅	EV/EBITDA ⇅	P/B ⇅	Gross M ⇅	Rev gr ⇅	EPS gr ⇅	FCF yld ⇅
CDT ★	$0B	—	—	—	-0.1	-0.0	—	—	—	9088.49%
LLY	$1,051B	41.8	26.3	14.6	30.1	33.8	82.8%	55.5%	169.9%	0.87%
UNH	$387B	32.1	19.2	0.9	17.7	4.0	19.5%	0.4%	61.5%	5.88%
JNJ	$609B	29.3	19.7	6.2	18.4	7.5	68.1%	6.6%	-1.0%	—
MRK	$315B	36.0	13.2	4.8	12.1	6.9	76.7%	4.9%	—	4.46%
ABBV	$450B	124.8	15.6	7.2	17.2	-67.6	72.0%	12.4%	-46.2%	4.63%
PFE	$143B	19.1	8.8	2.3	7.6	1.6	74.8%	5.4%	-10.1%	8.67%
TMO	$198B	29.2	19.5	4.4	21.1	3.8	40.9%	6.2%	11.3%	2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 0.16%

Holder	Shares	% out
Financial Management Professionals,	10,005	0.16%
Tower Research Capital LLC (TRC)	110	—
Morgan Stanley	2	—

Insider activity · 90d

1 buys / 4 sells · ratio 0.25 · Finnhub

Taylor Mark Andrew SELL 0 @ $1.40
Taylor Mark Andrew SELL 593,289 @ $0.75
Taylor Mark Andrew SELL 0 @ $1.44
Taylor Mark Andrew SELL 1,464,711 @ $0.71
Regan Andrew BUY 256,393 @ $1.90

Analyst estimates

yfinance

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low

$—

Mean

$—

High

$—

Analysts

—

Consensus: none (mean None). Distribution requires FINNHUB_API_KEY.

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

Form	Filed	Description	Action
8-K	2026-07-16	8-K	view ·
10-Q	2026-07-15	10-Q	view ·
8-K	2026-07-07	8-K	view ·
8-K	2026-06-29	8-K	view ·
4	2026-06-23	Insider transaction (Form 4)	view ·
8-K	2026-06-16	8-K	view ·
8-K	2026-05-28	8-K	view ·
8-K	2026-05-15	8-K	view ·
4	2026-05-14	Insider transaction (Form 4)	view ·
8-K	2026-04-27	8-K	view ·
10-K	2026-04-15	10-K	view ·
4	2026-03-30	Insider transaction (Form 4)	view ·
8-K	2026-03-25	8-K	view ·
8-K	2026-03-18	8-K	view ·
8-K	2026-03-09	8-K	view ·
DEF 14A	2026-03-06	DEF 14A	view ·
8-K	2026-02-24	8-K	view ·
4	2026-02-23	4	view ·
8-K	2026-01-22	8-K	view ·
8-K	2026-01-02	8-K	view ·
4	2025-12-22	4	view ·
8-K	2025-12-12	8-K	view ·
10-Q	2025-11-13	10-Q	view ·
8-K	2025-10-09	8-K	view ·
4	2025-09-22	Insider transaction (Form 4)	view ·
4	2025-09-19	Insider transaction (Form 4)	view ·
4	2025-08-26	4	view ·
4	2025-08-26	4	view ·
4	2025-08-26	4	view ·
10-Q	2025-08-14	10-Q	view ·
8-K	2025-08-14	8-K	view ·
8-K	2025-08-08	8-K	view ·
DEF 14A	2025-07-08	DEF 14A	view ·
4	2025-06-13	Insider transaction (Form 4)	view ·
8-K	2025-06-09	8-K	view ·
8-K	2025-06-03	8-K	view ·
8-K	2025-05-16	8-K	view ·
10-Q	2025-05-15	10-Q	view ·
8-K	2025-05-06	8-K	view ·
DEF 14A	2025-04-25	Proxy statement	view ·
8-K	2025-04-25	Material event (8-K)	view ·
4	2025-04-17	Insider transaction (Form 4)	view ·
8-K	2025-04-16	Material event (8-K)	view ·
8-K	2025-04-04	Material event (8-K)	view ·
4	2025-04-01	Insider transaction (Form 4)	view ·
4	2025-04-01	Insider transaction (Form 4)	view ·
4	2025-04-01	Insider transaction (Form 4)	view ·
4	2025-04-01	Insider transaction (Form 4)	view ·
8-K	2025-04-01	Material event (8-K)	view ·
10-K	2025-03-28	Annual report (10-K)	view ·
8-K	2025-03-06	Material event (8-K)	view ·
8-K	2025-02-19	Material event (8-K)	view ·
8-K	2025-02-11	Material event (8-K)	view ·
8-K	2025-01-23	Material event (8-K)	view ·
8-K	2025-01-14	Material event (8-K)	view ·
4	2024-12-20	Insider transaction (Form 4)	view ·
4	2024-12-20	Insider transaction (Form 4)	view ·
4	2024-12-20	Insider transaction (Form 4)	view ·
4	2024-12-20	Insider transaction (Form 4)	view ·
8-K	2024-12-20	Material event (8-K)	view ·

About CDT

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Options picks · CDT

ITM + OTM ideas from the latest scan

Loading…

Congress trades · CDT

STOCK Act disclosures

Loading…

SEC filings & insiders · CDT

EDGAR · live

Loading…

Holders · CDT

Institutions & insider activity

Loading…

CDT Equity Inc. NCM · CDT

Price chart

Latest bar · CDT

Financial overlay · last 12 quarters

Compare CDT vs peers

Earnings replay · last 0 reports

Peer comparison · Healthcare

Ownership

Top institutional holders

Insider activity · 90d

Analyst estimates

SEC filings

About CDT

Options picks · CDT

Congress trades · CDT

SEC filings & insiders · CDT

Holders · CDT

Filing summary